“AstraZeneca confident in $80 billion revenue by 2030 despite Ultomiris phase 3 failure”

AstraZeneca’s rare disease treatment Ultomiris failed to meet the primary endpoint in a phase 3 trial, and development of two internally developed antibody-drug conjugate (ADC) candidates has also been discontinued. The drug generated $1.31 billion in second-quarter revenue, up 12%, but fell short of market expectations, while the company’s total second-quarter revenue reached $15.4 billion. The company said it could achieve its $80 billion revenue target by 2030 based on a phase 3 success rate of approximately 60%, without additional mergers and acquisitions.